Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Bausch Health Companies Inc (BHC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,222,858
  • Shares Outstanding, K 349,757
  • Annual Sales, $ 8,724 M
  • Annual Income, $ 2,404 M
  • 36-Month Beta 0.63
  • Price/Sales 1.00
  • Price/Cash Flow 1.92
  • Price/Book 2.60

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate 0.88
  • Number of Estimates 5
  • High Estimate 0.97
  • Low Estimate 0.78
  • Prior Year 0.89
  • Growth Rate Est. (year over year) -1.12%

Price Performance

See More
Period Period Low Period High Performance
1-Month
22.45 +4.72%
on 02/20/19
26.17 -10.16%
on 02/20/19
+0.42 (+1.82%)
since 01/18/19
3-Month
17.20 +36.69%
on 12/26/18
26.17 -10.16%
on 02/20/19
+0.40 (+1.73%)
since 11/21/18
52-Week
14.44 +62.81%
on 03/02/18
28.45 -17.36%
on 10/03/18
+4.90 (+26.33%)
since 02/21/18

Most Recent Stories

More News
Bausch (BHC) Q4 Earnings Beat Estimates, Revenues Down Y/Y

Bausch (BHC) Q4 earnings and revenues surpass estimates. However, guidance for 2019 is not impressive.

BHC : 23.51 (-2.25%)
GSK : 40.54 (-1.98%)
ETON : 7.29 (-0.27%)
BMY : 50.13 (-2.28%)
Bausch Health (BHC) Surpasses Q4 Earnings and Revenue Estimates

Bausch (BHC) delivered earnings and revenue surprises of 19.32% and 1.33%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

BHC : 23.51 (-2.25%)
What's in the Cards for Bausch Health (BHC) Q4 Earnings?

Investors are looking forward to Salix and Bausch+Lomb's performance, and other pipeline updates when Bausch (BHC) reports Q4 results on Feb 20.

ACAD : 22.26 (-2.45%)
MNK : 20.52 (-3.30%)
BHC : 23.51 (-2.25%)
REPH : 8.40 (-2.21%)
Bausch (BHC) Upgraded to Strong Buy: Here's Why

Bausch (BHC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

BHC : 23.51 (-2.25%)
Alexion (ALXN) to Report Q4 Earnings: What's in the Cards?

Alexion's key drug like Soliris should drive growth in the fourth quarter of 2018.

REGN : 418.62 (-0.92%)
BHC : 23.51 (-2.25%)
HALO : 16.61 (-1.54%)
ALXN : 127.55 (-1.76%)
Is Bausch Health (BHC) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

BHC : 23.51 (-2.25%)
Has Bausch Health Cos (BHC) Outpaced Other Medical Stocks This Year?

Is (BHC) Outperforming Other Medical Stocks This Year?

BHC : 23.51 (-2.25%)
Dr. Reddy's (RDY) to Report Q3 Earnings: What's in Store?

Dr. Reddy's has launched few generics which should add to revenues of the company when the company releases its third-quarter fiscal 2019 results.

RDY : 36.00 (+0.64%)
AGN : 136.60 (-2.66%)
LLY : 122.72 (+0.05%)
BHC : 23.51 (-2.25%)
Why Bausch (BHC) is Poised to Beat Earnings Estimates Again

Bausch (BHC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

BHC : 23.51 (-2.25%)
Bausch Health (BHC) Gains But Lags Market: What You Should Know

Bausch Health (BHC) closed at $22.34 in the latest trading session, marking a +0.4% move from the prior day.

BHC : 23.51 (-2.25%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade BHC with:

Business Summary

Bausch Health Companies Inc. develops and distributes drugs. It develops drugs for unmet medical needs in central nervous system disorders and distributes generic and branded generic drugs primarily in Latin America and Eastern Europe. Bausch Health Companies Inc., formerly known as Valeant Pharmaceuticals,...

See More

Key Turning Points

2nd Resistance Point 25.18
1st Resistance Point 24.34
Last Price 23.51
1st Support Level 23.05
2nd Support Level 22.60

See More

52-Week High 28.45
Last Price 23.51
Fibonacci 61.8% 23.10
Fibonacci 50% 21.44
Fibonacci 38.2% 19.79
52-Week Low 14.44

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar